Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFAR in High-Risk Previously Untreated CLL
NCT00525603Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2005
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00525603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525603.